RE:RE:RE:RE:Another therapeutic for COVID CancerSlayer wrote: tdon1229 wrote: Pandora wrote:
Yes, collaborating with big money pharma again. In the meantime Cytodyn (CYDY) has done a trial on the mild to mid group and have just completed a blinded study on severe to critical patients (390) with results to be posted mid-January. No collaboration there even though it has possibly the best results of any therapeutic thus far -- but having to wait for numbers.
They have also now started a trial for what is termed the "long-haulers".
https://finance.yahoo.com/news/fda-resumes-eind-approval-severe-110000503.html
And when they realize that CCR5 is over expressed in the brains of stroke victims, maybe they'll get still another trial opportunity with leronlimab, which is a CCR5 agonist.
Hi Tdon. Just wanted to clarify Leronlimab is a CCR5 "antagonist", which is probably what you meant. Controlling the exaggerated immune response or cytokine/chemokine storm will play a major role in treating the severely ill/hospitalized.
Theralase has a realistic opportunity to reduce hospitalizations in the future with its focus on an alternative/better vaccine & potential outpatient therapeutic. Also, unlike many immunomodulators, gene therapies & other single-target antivirals, the multimodal mechanism of action of TLD-1433/PDT may reduce selection pressure/pathogen resistance.
I see organometallics making significant strides in medicine...and Ruthenium & its assorted ligands are at the top of a short list. Throw in optimized PDT or targeted radiation, we may just be on the verge of a "universal" treatment/medical breakthrough...All imo.
Yes, CS, a "CCR5 antagonist" is what I meant to say ... my dancing fingertips skipped over a few letters and changed the meaning. Thank you for pointing that out.
As for the potential for a universal treatment, from your lips to God's ear. However, until Theralase gets some SP traction, or gains a partnership or three, progress towards that goal will be limited by financial concerns and will continue to be painstakingly slow.